SUCCESSFUL CLEARANCE OF CHRONIC NOROVIRAL INFECTION BY RIBAVIRIN IN A PATIENT WITH COMMON VARIABLE IMMUNODEFICIENCY-ASSOCIATED ENTEROPATHY RESULTS IN COMPLETE SYMPTOMATIC AND HISTOPATHOLOGICAL RESOLUTION

doi:10.1136/gutjnl-2012-302514c.160

1 J Woodward,* 2 A Ng, 3 A Aravinthan, 4B Bandoh, 4H Liu, 5 S Davies, 5 P Stevenson, 2 M Curran, 5 D Kumararatne. 1 Gastroenterology, Clinical Microbiology and Public Health Laboratory, Cambridge, UK; 2 Health Protection Agency, Clinical Microbiology and Public Health Laboratory, Cambridge, UK; 3 Hepatology, Addenbrookes Hospital, Cambridge, UK; 4 Histopathology, Addenbrookes Hospital, Cambridge, UK; 5 Clinical Biochemistry and Immunology, Addenbrookes Hospital, Cambridge, UK

Introduction We have recently demonstrated an association between chronic Noroviral infection and Common Variable Immunodeficiency-associated (CVID) enteropathy. Here we describe a patient with CVID enteropathy treated with Ribavirin.

Methods A 33-year-old lady with known CVID presented to our service in 2008 with 20% weight loss, nausea and profuse diarrhoea. Investigations revealed classical appearances of CVID enteropathy with subtotal duodenal villous atrophy, but no evidence of bacterial, enteroviral or parasitic infection. Treatment with gluten withdrawal, elemental diet, and budesonide were largely ineffective and she required parenteral nutrition for malabsorption and anti-TNF therapy with Infliximab and subsequently Humira for symptom relief. No therapy changed the degree of villous atrophy. Following 6 years of symptoms, stool was noted to be positive on PCR for Norovirus RNA. Retrospective analysis of archived duodenal biopsies revealed the presence of Noroviral RNA in all biopsies from 2005 to 2009 and RNA sequencing showed this to be the same strain of virus throughout. In view of reported in vitro activity of Ribavirin against Norovirus, this agent was commenced with therapeutic level monitoring and quantitative stool PCR for Norovirus excretion.

Results Once Ribavirin levels were >1000 ng/ml, quantitative PCR demonstrated a reduction in Noroviral excretion which then became undetectable. Simultaneously, the patient reported dramatic symptomatic relief with a change from profuse diarrhoea to two formed motions a day, no nausea and return of appetite. Parenteral nutrition and Humira were stopped. Duodenal biopsies after 3 months showed complete resolution of villous morphology and were negative for Norovirus on PCR. Stool remained negative for Noroviral RNA. After 6 months Ribavirin therapy was stopped. The patient has remained asymptomatic for the subsequent 9 months with no evidence of recurrent Noroviral excretion.

Conclusion Complete resolution of symptoms and duodenal villous atrophy with clearance of the Norovirus suggests that the association of Norovirus infection with CVID enteropathy is causal. Ribavirin may have activity against Norovirus in vivo and this first ever demonstration of a cure for this condition requires confirmation in other cases.

Competing interests None declared.

CAPSULE ENDOSCOPY: DIAGNOSTIC YIELD AND CLINICAL OUTCOMES IN NORTH-EAST LINCOLNSHIRE

doi:10.1136/gutjnl-2012-302514c.162

J R White,* R Mudawi, A Naqvi, S Enaganti. Gastroenterology, Diana, Princess of Wales Hospital, Grimsby, UK

Introduction Capsule Endoscopy (CE) has become a very important non-invasive tool for the investigation of small bowel pathology. This study examines the patient pathway to CE, from initial referral to final clinical outcome, within our newly established service.

Methods Medical notes for patients who underwent CE in North East Lincolnshire from 2009 to 2011 were reviewed retrospectively. Information analysed included demographics, previous investigation, diagnosis and subsequent treatment.

Results 123 patients underwent CE in the 2-year study period. 22 notes were unobtainable, so 101 were analysed. The study population characteristics include a median age of 59 (16–76 yrs), an equal gender spread (53% female and 47% male) with a 99% white ethnic majority. 95% of referrals were as an outpatient and 92% were made by physicians. The median waiting time was 115 days. The main indications were: recurrent iron deficiency anaemia (48.5%), inflammatory bowel disease (IBD) (33.7%), overt gastrointestinal (GI) bleeding (15%). Patients had commonly undergone previous investigations: marjority had gastroscopy, colonoscopy (82.3%), CT abdomen (22.8%), Barium meal (21.8%), small bowel MRI (18.8%) and flexi-sigmoidoscopy (9.9%). 6% (7 patients) had undergone a previous CE. CE detected abnormality in 97% of this cohort, although some were insignificant. The most common pathology was: erosions (54.5%), evidence of blood (41.6%), angiodysplastic lesions (52.6%), ulceration (28.7%), focal inflammation (26.7%) and upper GI inflammation (19.8%). 72.2% of pathology was in the small bowel. Procedural complications included capsule retention (2), and suboptimal views in four patients. CE reporting confirmed diagnoses of angiodysplasia (25.7%), IBD (16.8%), drug induced small bowel erosions (6.9%), duodenitis/gastritis/oesophagitis (5.9%) and ulceration (4.9%). Rarer diagnoses included small bowel tumour and Meckel’s Diverticulum. Median reporting time was 35 days. CE significantly contributed to the management of the patients examined: 78% had changes to their medications (e.g. stop NSAIDs, start IBD drugs), 62% underwent further
investigations (eg, enteroscopy, gastroscopy and colonoscopy), 52% underwent therapeutic intervention (eg, APC, polypectomy and surgical referral). However, in 30% their management was unchanged. The majority of patients (88.1%) are still under active follow-up today.

**Conclusion**

The CE experience at this centre is of a simple, well-tolerated investigation which allows definite diagnoses to be made with minimal complications. Higher diagnostic yield compared to previous published data could be explained by the strict inclusion criteria and recent introduction of this new service. This expanding service highlights the need for more resources to reduce waiting and reporting times in line with other GI investigations.

**Competing interests**

None declared.

---

**PTU-163 DEPRESSION AND CARCINOID SYNDROME: IS THERE ANY RELATIONSHIP? A CROSS-SECTIONAL STUDY**

doi:10.1136/gutjnl-2012-302514c.163

1J Garcia-Hernandez,* 1M Mohmadovesh, lP Davies, lC Toumpanakis, lJ R Goodhand, lM Caplin, 2D Skuse, lRoyal Free Hospital, London, UK; 2UCLH, London, UK

**Introduction**

The relationship between brain serotonin and depression is well established. It is also widely accepted that serotonin hyperproduction in carcinoid syndrome does not cross the blood-brain barrier. CNS serotonin is synthesised from tryptophan within serotonergic neurons and a deficiency of this precursor could be possible on carcinoid patients. In this cross-sectional study we evaluated, whether the feelings of depression are associated with neuroendocrine symptomatology. In addition, whether self-report of quality of life is associated with feelings of depression.

**Methods**

47 patients with carcinoid syndrome completed a survey via clinic involving: QoL questionnaires and the Beck’s Depression Inventory-II (BDI-II). All questionnaires were counterbalanced.

**Results**

45 out of 47 patients had low scores on the BDI-II and not likely to suffer from depression. Only two participants had moderate depression scores. These scores were negatively associated with self-report of QoL. t = -0.59, N = 46, p <0.001. Interestingly, endocrine symptoms that is, flushing and night sweats, were not associated with depressive symptoms: r = 0.22, N = 44, p = 0.15, whereas, gastrointestinal symptoms that is, diarrhoea, abdominal discomfort, bloatedness and indigestion, were strongly associated with depression scores: r = 0.56, N = 43, p <0.001.

**Conclusion**

Depressive scores in carcinoid patients are often attributed to the stress of diagnoses and adaptation to this chronic disease, however, although a causal relationship has not been established between carcinoid and depression, physicians should consider this possibility when psychological symptoms do not improve with conventional therapy. Further research is needed to understand why gastrointestinal, and not endocrine, symptoms were correlated with depressive symptoms.

**Competing interests**

None declared.

---

**REFERENCES**


